Pulse Biosciences said it will prioritize development and future commercialization of its nPulse cardiac catheter ablation system by shifting capital allocation toward its electrophysiology program. The company plans to direct most R&D and clinical investment to an upcoming pivotal IDE study in the U.S. and Europe and related regulatory submissions. Pulse Biosciences said it will reduce short-term market development spending in cardiac surgery while continuing Surgical Clamp IDE enrollment. The company also plans to streamline operations for its percutaneous soft-tissue ablation system and focus market development on progressing the Vybrance percutaneous electrode system toward an on-label indication for benign thyroid nodules. Pulse Biosciences said additional 12-month follow-up data on the cardiac catheter program is scheduled for presentation at Heart Rhythm 2026 on April 25.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317606748) on March 17, 2026, and is solely responsible for the information contained therein.